Sun X, Gemzell-Danielsson K, Li H, Ståbi B, Stavreus-Evers A. Expression of heparin-binding epidermal growth factor-like growth factor and its receptors in the human fallopian tube and endometrium after treatment with mifepristone. Fertil Steril. 2006;85:171-8 pubmed

Woo R, Lee J, Yu H, Song D, Baik T. Expression of ErbB4 in the apoptotic neurons of Alzheimer's disease brain. Anat Cell Biol. 2010;43:332-9 pubmed

Mukhopadhyay P, Lakshmanan I, Ponnusamy M, Chakraborty S, Jain M, Pai P, et al. MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells. PLoS ONE. 2013;8:e54455 pubmed publisher

Jackson-Fisher A, Bellinger G, Shum E, Duong J, Perkins A, Gassmann M, et al. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene. 2006;25:5664-72 pubmed

Mimura S, Yamaguchi T, Ishii S, Noro E, Katsura T, Obuse C, et al. Cul8/Rtt101 forms a variety of protein complexes that regulate DNA damage response and transcriptional silencing. J Biol Chem. 2010;285:9858-67 pubmed publisher

Woo R, Lee J, Yu H, Song D, Baik T. Expression of ErbB4 in the neurons of Alzheimer's disease brain and APP/PS1 mice, a model of Alzheimer's disease. Anat Cell Biol. 2011;44:116-27 pubmed

Intoh A, Kurisaki A, Yamanaka Y, Hirano H, Fukuda H, Sugino H, et al. Proteomic analysis of membrane proteins expressed specifically in pluripotent murine embryonic stem cells. Proteomics. 2009;9:126-37 pubmed publisher

Hahn C, Wang H, Cho D, Talbot K, Gur R, Berrettini W, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006;12:824-8 pubmed

Di Cara G, Marengo G, Albanese N, Marabeti M, Musso R, Cancemi P, et al. Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells. Anticancer Res. 2013;33:489-503 pubmed

Woo R, Lee J, Kim H, Baek C, Song D, Suh Y, et al. Neuregulin-1 protects against neurotoxicities induced by Swedish amyloid precursor protein via the ErbB4 receptor. Neuroscience. 2012;202:413-23 pubmed publisher

Rösler T, Depboylu C, Arias-Carrión O, Wozny W, Carlsson T, Höllerhage M, et al. Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1. Neuropharmacology. 2011;61:1413-8 pubmed publisher

Asadurian Y, Kurilin H, Lichtig H, Jackman A, Gonen P, Tommasino M, et al. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J Med Virol. 2007;79:1751-60 pubmed

Wilson K, Mill C, Gallo R, Cameron E, VanBrocklin H, Settleman J, et al. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. Biochem J. 2012;443:133-44 pubmed publisher

Gilmore-Hebert M, Ramabhadran R, Stern D. Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways. Mol Cancer Res. 2010;8:1388-98 pubmed publisher

Mill C, Gettinger K, Riese D. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res. 2011;317:392-404 pubmed publisher

Ryu J, Yu H, Cho H, Kim H, Baik T, Lee S, et al. Neuregulin-1 exerts protective effects against neurotoxicities induced by C-terminal fragments of APP via ErbB4 receptor. J Pharmacol Sci. 2012;119:73-81 pubmed

Sanui A, Yotsumoto F, Tsujioka H, Fukami T, Horiuchi S, Shirota K, et al. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res. 2010;30:3143-9 pubmed